Strensiq
Named-patient access overview. Strensiq is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Strensiq (asfotase alfa) is a bone-targeted recombinant human tissue-nonspecific alkaline phosphatase enzyme replacement therapy developed by Alexion (AstraZeneca Rare Disease). It is approved by the US FDA for perinatal/infantile-onset and juvenile-onset hypophosphatasia. The standard regimen is 2 mg/kg subcutaneous three times weekly or 1 mg/kg subcutaneous six times weekly. Strensiq is available in the global pharmaceutical supply chain in 18 mg, 28 mg, 40 mg, 80 mg per mL single-use vials.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Strensiq
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Strensiq is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Strensiq in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Strensiq
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.